Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 4 open-label study of Ozurdex in treatment-naive diabetic macular edema
2018-004785-33Phase 4Completed
- Sponsor
- Allergan
- Start
- Apr 2019
- Modality
- Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ozurdex in diabetic macular edema (DME), sponsored by Allergan. Primary endpoint: Mean change in best corrected visual acuity after last injection. Started Apr 2019; status: completed.
02
Drugs
ozurdex
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2018-004785-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004785-33.